Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2011-04-04 | Algeta (Norway) Genzyme (USA - MA) | thorium platform | tumors, cancers | R&D |
Cancer - Oncology | R&D agreement |
2011-04-04 | Selvita (Poland) The Institutes for Pharmaceutical Discovery (USA) | novel chemical compounds that inhibit the activity of a novel protein target, proposed by IPD | undisclosed | R&D |
undisclosed | R&D agreement |
2011-04-04 | Cellectis (France) undisclosed drug company | homologous recombination technology | licensing |
Cancer - Oncology | Licensing agreement | |
2011-03-31 | Cytos Biotechnology (Switzerland) United States Army (USA) | malaria vaccine | malaria | development |
Infectious diseases - Parasitic diseases | Development agreement |
2011-03-30 | MedImmune (USA) Inserm Transfert (France) Inserm (France) | collaboration |
Cancer - Oncology - Respiratory diseases - Inflammatory diseases - Autoimmune diseases | Collaboration agreement | ||
2011-03-30 | Graffinity (Germany) Shionogi (Japan) | small molecule hits against an undisclosed key drug target | undisclosed | R&D |
undisclosed | R&D agreement |
2011-03-30 | NovAliX (France) Graffinity Pharmaceuticals (Germany) Shionogi (Japan) | novel small molecule hits against an undisclosed drug target | undisclosed | R&D |
undisclosed | R&D agreement |
2011-03-29 | Protagen (Germany) Biogen Idec (USA) | biomarkers | multiple sclerosis | Collaboration |
Autoimmune diseases - Neurodegenerative diseases | R&D agreement |
2011-03-28 | MolMed (Italy) Fondazione Telethon (Italy) | gene therapy treatments for six rare genetic diseases | metachromatic leukodystrophy (MLD) - Wiskott-Aldrich syndrome (WAS) - beta-thalassemia mucopolysaccharidosis type I (MPS I) - globoid leukodystrophy (GLD) - chronic granulomatous disorder (CGD) | development |
Rare diseases - Genetic diseases | Development agreement |
2011-03-25 | AstraZeneca (UK) Senectus Therapeutics (UK) | screening of a selection of AstraZeneca’s chemical compound library | services |
Cancer - Oncology | Services contract | |
2011-03-23 | Sanofi-Aventis (France) The Vision Institute (France) | R&D |
Ophtalmological diseases | R&D agreement | ||
2011-03-23 | Debiopharm (Switzerland) Aurigene (India) | Debio 1142 | licensing |
Cancer - Oncology | Licensing agreement | |
2011-03-22 | Vivalis (France) Okairos (Italy) | EB66® cell line | licensing |
Infectious diseases | Licensing agreement | |
2011-03-21 | Karo Bio (Sweden) Zydus Cadila (India) | novel anti-inflammatory drug compounds which affect glucocorticoid receptors in a selective manner. | R&D |
Inflammatory diseases | R&D agreement | |
2011-03-21 | Dako (Denmark) Epitomics (USA) | rabbit monoclonal antibodies to be used in diagnosing cancer and in developing predictive assays for cancer patients (companion diagnostics) | collaboration |
CancerOncology | Collaboration agreement | |
2011-03-17 | Epistem (UK) Sanofi-Aventis (France) | biomarker gene expression profiling and immunohistochemistry technologies | R&D licensing |
Licensing agreement | ||
2011-03-17 | Lonza (Switzerland) Athera Biotechnologies (Sweden) | PC-mAb (monoclonal antibody to phosphorylcholine) | acute coronary syndrom | development |
Cardiovascular diseases | Development agreement |
2011-03-16 | MorphoSys (Germany) Boehringer Ingelheim (Germany) | MOR208 ( anti-CD19 monoclonal antibody) | chronic lymphocytic leukemia and potentially other B-cell malignancies | manufacturing |
Cancer - Oncology | Production agreement |
2011-03-15 | Depomed (USA) Boehringer Ingelheim (Germany) | Acuform® Technology and Glumetza® Data | type 2 diabetes | licensing |
Metabolic diseases | Licensing agreement |
2011-03-15 | InhibOx (UK) Cosmic Discoveries (India) | drug discovery services | collaboration |
Collaboration agreement |